Oncimmune profiles the body’s immune response to detect evidence of the body’s natural response to cancer, which can be detected far earlier than cancerous cells themselves, or the cancer’s DNA.
Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT—Lung and EarlyCDT—Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT—Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland.
Oncimmune is headquartered in Nottingham (UK) with a CLIA lab in Kansas (US) and offices in London (UK), Dortmund (Germany) and Shanghai (China).
Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016.
Oncimmune acquired the immuno-profiling company PROTAGEN AG in March 2019.
Our proprietary platform — underpinned by rapid biomarker discovery and our comprehensive immunogenic protein library of over 8,000 antigenic proteins — has a role in supporting case-selection, complementing diagnostic evidence, and facilitating therapeutic decision-making; and is a keystone to the future of cancer care.
Our patented technology measures blood levels of autoantibodies to tumour-associated antigens, the combination of which is highly specific for target cancers, whose characteristic signal can be detected four years or more before standard clinical diagnosis.
Oncimmune is working to change how cancer is diagnosed and treated. Whilst early detection is already improving cancer survival, immuno-profiling is the frontier to improving outcomes.
Key Fundamentals 31-May-15 31-May-16 31-May-17 31-May-18
Revenue (£ m) 1.34 0.43 0.22 0.24
Pre-Tax (£ m) -2.01 -9.01 -5.32 -6.34
As at 30th April 2019, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company:
No of Ordinary Shares %
• BALDERTON CAPITAL III, LP1 10.8
• GENOSTICS COMPANY LTD2 10.1
• Richard Sharp 7.1
• RUFFER LLP 5.3
• Geoffrey Hamilton-Fairley 5.1
• FIL INVESTMENT INTERNATIONAL 4.9
• Timothy Bunting 4.4
• MILTON ASSET MANAGEMENT 4.0
• UNIVERSITY OF NOTTINGHAM 3.5
1 Thane Road
|ONCIMMUNE HOLDINGS LIMITED||2015-10-09 - 2015-12-21|
- 4573 Biotechnology
- Company Number
- Public Limited Company
- Company Age
- 5 years
- October 9, 2015
- Nature of Business
- 70100 - Activities of head offices
- Year End
- May 31
- Accounts Due
- November 30, 2021
- Latest Accounts
- May 31, 2020
Oncimmune is working to change how cancer is diagnosed and treated.
ONCIMMUNE HOLDINGS PLC ORD 1P (ONC.L) Stock Price, News ...Source:finance.yahoo.com
3 days ago ... Find the latest ONCIMMUNE HOLDINGS PLC ORD 1P (ONC.L) stock quote, history, news and other vital information to help you with your ...
Oncimmune has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development ...
Oncimmune Holdings PLC - Company Profile and News ...Source:www.bloomberg.com
Oncimmune Holdings plc operates as a cancer detection company. The Company focuses on the development of autoantibody assay technologies that allow ...
ONCIMMUNE HOLDINGS PLC ONC Stock | London Stock ExchangeSource:www.londonstockexchange.com
ONCIMMUNE HOLDINGS PLC ONC Company page - Search stock, chart, recent trades, company information, trading information, company news, ...
Oncimmune Holdings PLC (ONC : LON) Stock Price & News ...Source:www.google.com
3 days ago ... Get the latest Oncimmune Holdings PLC (ONC) real-time quote, historical performance, charts, and other financial information to help you make ...